ArticleJournal of parasitology research2026
Control of Human African Trypanosomiasis in the Nola-Bilolo Focus, Central African Republic, 2020-2024: Outcome of Capacity Building, Improved Diagnosis and Treatment.
Article in Journal of parasitology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Control of Human African Trypanosomiasis in the Nola-Bilolo Focus, Central African Republic, 2020-2024: Outcome of Capacity Building, Improved Diagnosis and Treatment.Journal of parasitology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study is aimed at evaluating the inclusion of miniature anion-exchange centrifugation technique (mAECT) in the diagnosis and fexinidazole as treatment of gHAT in Central African Republic (CAR) after capacity building. A cross-sectional pilot study was conducted during a mass diagnostic campaign from 16 September to 22 October 2022 in Nola-Bilolo, a historic focus in CAR. The serological test, card agglutination test for trypanosomiasis (CATT), was performed on whole blood and diluted plasma to screen participants, followed by a confirmatory parasitological test by capillary tube centrifugation (CTC) and mAECT. Positive cases were treated mainly with fexinidazole. A total of 2070 participants were screened, out of an estimated population of 3584, representing a participation rate of 58%. The seroprevalence of HAT was 1.6% (CI 95%: 77%-99%) (33/2070) by the CATT plasma end-dilution titre ≥ 1:16. Blood from serological subjects was examined microscopically after concentration by CTC and mAECT was positive for trypanosomes in 48.48% (CI 95%: 31%-66%) (16/33) and 87.88% (CI 95%: 77%-99%) (29/33) of cases, respectively. The prevalence of microscopically confirmed HAT was 0.77% (CI 95%: 0.40%-1.15%) and 1.4% (CI 95%: 1%-2%) by CTC and mAECT, respectively. Twenty-one (72.41%) patients were treated with fexinidazole with a 0% interruption rate. The introduction of fexinidazole (2021) and mAECT (2022) likely contributed to the rise in reported cases (from 45 in 2021 to 111 in 2024) and improved screening coverage in the study area, reflecting enhanced case detection and access to care. There is a necessity to establish diagnostic quality assurance and to reinforce the other control measures including vector control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.